The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinicopathologic features and outcomes of de novo transformed indolent lymphoma.
 
Collin K Chin
No Relationships to Disclose
 
Chan Cheah
No Relationships to Disclose
 
Preetesh Jain
No Relationships to Disclose
 
Nathan Hale Fowler
Consulting or Advisory Role - Bayer; Celgene; Novartis; Roche/Genentech; TG Therapeutics; Verastem
Research Funding - Abbvie; BeiGene; Celgene; Gilead Sciences; Novartis; Roche; TG Therapeutics
 
Luis Fayad
No Relationships to Disclose
 
Jason Westin
Consulting or Advisory Role - Amgen; Celgene; Curis; Genentech/Abbvie; Janssen Scientific Affairs; Juno Therapeutics; Juno Therapeutics; Kite/Gilead; MorphoSys; Novartis
Research Funding - Bristol-Myers Squibb; Celgene; Curis; Genentech; Janssen; Kite/Gilead; Novartis
 
Maria Alma Rodriguez
Research Funding - Amgen (Inst); GlaxoSmithKline (Inst); Ortho Biotech (Inst); Pfizer (Inst)
 
Mansoor Noorani
No Relationships to Disclose
 
Sattva Swarup Neelapu
Honoraria - Aptitude Health; Bio Ascend; Medscape; MJH Life Sciences
Consulting or Advisory Role - Alimera Sciences; Celgene; Cell Medica; Gilead Sciences; Incyte; Kite, a Gilead company; Legend Biotech; Merck Sharp & Dohme; Novartis; Pfizer; Precision Biosciences; Unum Therapeutics
Research Funding - Acerta Pharma; Alimera Sciences; Bristol-Myers Squibb; Cellectis; Gilead Sciences; Karus Therapeutics; Kite, a Gilead company; Merck Sharp & Dohme; poseida therapeutics; Precision Biosciences; Unum Therapeutics
Patents, Royalties, Other Intellectual Property - Patents related to cellular therapy
Travel, Accommodations, Expenses - Alimera Sciences; Celgene; Chugai Pharma; Kite/Gilead; Legend Biotech; Medscape; Merck; Novartis; Pfizer; Precision Biosciences; Unum Therapeutics
 
Fredrick B. Hagemeister
No Relationships to Disclose
 
L Jeffrey Medeiros
No Relationships to Disclose
 
Francisco Vega
No Relationships to Disclose
 
Felipe Samaniego
No Relationships to Disclose
 
Christopher Flowers
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeiGene; Celgene; Denovo Biopharma; Genentech/Roche; Gilead Sciences; Karyopharm Therapeutics; MEI Pharma; Pharmacyclics/Janssen; Spectrum Pharmaceuticals
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); BeiGene (Inst); Celgene (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immune Design (Inst); Janssen Oncology (Inst); Millennium (Inst); Onyx (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Celgene; Genentech/Roche; Gilead Sciences
 
Loretta J. Nastoupil
Honoraria - Bayer; Celgene; Gamida Cell; Gilead Sciences; Janssen Oncology; Juno Therapeutics; Novartis; Pfizer; Spectrum Pharmaceuticals; TG Therapeutics
Research Funding - Celgene; Genentech/Roche; Janssen Biotech; Karus Therapeutics; LAM Therapeutics; TG Therapeutics